Colorectal cancer surveillance in inflammatory bowel disease: A critical analysis

Table 1 Risk of colorectal cancer in inflammatory bowel disease

Ref.	Type of study	Risk in UC	Risk in CD	Odds ratio (95%CI)	Comments
Eaden et al[8] 2001	Meta-analysis 116 studies; 41 mentioned duration of UC	3.7%		NA	2% at 10 yr, 8% at 20 yr, 18% at 30 yr
Jess et al[9] 2006	Population-based	6/378 (1.6%)	6/314 (1.9%)	SIR UC: 1.1 (0.4-2.4) CD: 1.9 (0.7-4.1)	Cumulative cancer risk 2% at 20 yr
Rutter et al[10] 2006	Hospital-based retrospective	3/600 (0.5%)	NA	NA	2.5% at 20 yr, 7.6% at 30 yr, 10.8% at 40 yr
Jess et al[11] 2012	Meta-analysis of 8 population-based (1958-2004)	1.6% (14 yr follow-up)	NA	Pooled SIR: 2.4 (2.1-2.7)	Risk of in patients with UC over
Lutgens et al[12] 2013	Meta-analysis (1988-2009)			IBD pooled SIR Population based: 1.7 (1.2-2.2)Referral based: 5.3 (2.8-7.8)
Jess et al[13] 2012	Population-based			RR for CRC- UC1979-1988: 1.34 (1.13-1.58) 1989-1998: 1.09 (0.9-1.33)1999-2008: 0.57 (0.41-0.80) RR for CRC in CD: 0.85 (0.67-1.07), which did not change over time	CRC risk in UC reduced over three decades and comparable to general population;CD no change
Herrinton et al[14] 2012	Hospital-based	UC 53 /10895CD 29/5603		UC: 1.6 (1.3-2.0) CD: 1.6 (1.2-2.0)	CRC risk in UC and CD 60% higher than population
Asian studies
Gilat et al[15] 1988	Population-based (central Israel)		NA		CRC risk in UC: 0.2% at 10 yr, 5.5% at 20 yr, 13.5% at 30 yr
Kochhar et al[16] 1992	Hospital-based (India)	UC 1.8%	NA
Venkataraman et al[17] 2005	Hospital-based (India)	UC 0.94%
Kim et al[19] 2009	Population-based (South Korea)	UC 0.50%
Kekilli et al[20] 2010	Hospital-based (Turkey)	UC 1.10%
Gong et al[21] 2012	Hospital-based (China)	UC 0.87%

CD: Crohn’s disease; FH: Family history; IBD: Inflammatory bowel disease; NA: Not applicable; PSC: Primary sclerosing cholangitis;